Trulieve Cannabis Consensus Analyst Rating and Stock Price Forecast (2024)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Analysts' Consensus Rating
Buy
Based on 3 Analyst Ratings
Analysts' Consensus Price Target
$14.88
71.37% Upside
| High Forecast | $37.00 |
|---|---|
| Average Forecast | $14.88 |
| Low Forecast | $6.00 |
| Type | Current Forecast 2/21/23 to 2/21/24 | 1 Month Ago 1/22/23 to 1/22/24 | 3 Months Ago 11/23/22 to 11/23/23 | 1 Year Ago 2/21/22 to 2/21/23 |
|---|---|---|---|---|
| Consensus Rating | Buy | Buy | Buy | Buy |
| Strong Buy | 0 Strong Buy rating(s) | 0 Strong Buy rating(s) | 0 Strong Buy rating(s) | 0 Strong Buy rating(s) |
| Buy | 3 Buy rating(s) | 3 Buy rating(s) | 3 Buy rating(s) | 4 Buy rating(s) |
| Hold | 0 Hold rating(s) | 0 Hold rating(s) | 0 Hold rating(s) | 0 Hold rating(s) |
| Sell | 0 Sell rating(s) | 0 Sell rating(s) | 0 Sell rating(s) | 0 Sell rating(s) |
| Consensus Price Target | $14.88 | $14.88 | $14.88 | $34.40 |
| Predicted Upside | 71.37% Upside | 177.63% Upside | 177.63% Upside | 140.20% Upside |
Get Trulieve Cannabis Upgrade and Downgrade Alerts
Sign-up to receive the latest news and ratings for TCNNF and its competitors with MarketBeat's FREE daily newsletter.
TCNNF Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
TCNNF Price Targets by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target History
Trulieve Cannabis Stock vs. The Competition
| Type | Trulieve Cannabis | Medical Companies | S&P 500 |
|---|---|---|---|
| Consensus Rating Score | 3.00 | 2.67 | 2.48 |
| Consensus Rating | Buy | Moderate Buy | Hold |
| Predicted Upside | 71.37% Upside | 917.80% Upside | 8.95% Upside |
| News Sentiment Rating | Neutral News | Positive News | Positive News |
Recent Analyst Ratings and Stock Forecasts
Export to Excel
| Date | Brokerage | Analyst Name | Action | Rating | Price Target | Upside/Downside on Report Date | Details |
|---|---|---|---|---|---|---|---|
| 11/9/2023 | Subscribe to MarketBeat All Access for the recommendation accuracy rating | Lower Target | Buy ➝ Buy | $9.00 ➝ $6.50 | +30.52% | ||
| 8/11/2023 | Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating | Lower Target | Outperform ➝ Outperform | $8.00 ➝ $6.00 | +44.93% | ||
| 8/10/2023 | Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating | Boost Target | C$8.00 ➝ C$9.00 | ||||
| 5/11/2023 | Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating | Lower Target | C$24.00 ➝ C$16.00 | ||||
| 3/9/2023 | Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating | Lower Target | $20.00 ➝ $10.00 | +59.49% | |||
| 3/6/2023 | Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating | Lower Target | Overweight | $41.00 ➝ $37.00 | +469.44% |
Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:56 AM ET.
TCNNF Price Target - Frequently Asked Questions
What is Trulieve Cannabis's consensus rating and price target?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Trulieve Cannabis stock is Buy based on the current 3 buy ratings for TCNNF. The average twelve-month price prediction for Trulieve Cannabis is $14.88 with a high price target of $37.00 and a low price target of $6.00. Learn more on TCNNF's analyst rating history.
Do Wall Street analysts like Trulieve Cannabis more than its competitors?
Analysts like Trulieve Cannabis more than other Medical companies. The consensus rating for Trulieve Cannabis is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how TCNNF compares to other companies.
Does Trulieve Cannabis's stock price have much upside?
According to analysts, Trulieve Cannabis's stock has a predicted upside of 177.63% based on their 12-month stock forecasts.
Stock Ratings Reports and Tools
Related Companies:
- BOIRF Analyst Rating
Today's Ratings:
- U.S. Ratings
- U.K. Ratings
- Canadian Ratings
- All Upgrades
- All Downgrades
- All Initiations
- All Price Target Changes
Top Rated Stocks:
- Top Rated Stocks
- Top Rated Dividend Stocks
- Top Rated Small-Cap Stocks
- Top Rated Tech Stocks
- Most Upgraded Stocks
- Most Downgraded Stocks
- Lowest Rated Stocks
More Ratings Tools:
- Stock Ratings by Company
- Stock Ratings by Issuer
- Top-Rated Analysts
- Top-Rated Brokerages
- Stock Ratings Screener
- Free Ratings Newsletter
